Lombardi Cancer Center receives $7 million

July 10, 2003

Washington, D.C. - The Lombardi Cancer Center at Georgetown University will establish a multi-institution Breast Cancer Center of Excellence to study the link between alcohol consumption and breast cancer. The Center, funded by a seven million dollar grant from the Department of Defense, will be led by Lombardi researchers and will also include investigators at the State University of New York at Buffalo, the National Cancer Institute, the Washington Hospital Center and the Catholic University.

Alcohol consumption is the best documented risk factor for causing breast cancer other than familial and hormonal risk factors, such as number of pregnancies and age at menopause. However, the reasons why drinking alcohol causes breast cancer have not been well studied.

Peter Shields, M.D., professor of medicine and director of cancer genetics and epidemiology at Georgetown University Medical Center, will serve as principal investigator, supervising this multicenter research effort to better understand the root mechanism behind this increased risk.

"Alcohol drinking causes about 17,000 new breast cancer cases per year," said Dr. Shields. "While seemingly low, it actually is not. This is the major known modifiable risk factor and affects about 4 times more women than those from high risk families. Just as we can learn a lot about women's risk in general by studying women from high risk families, the same also is true for the study of alcohol drinking, because it is a paradigm for other risk factors, such as diet."

Dr. Shields and his colleagues will test four hypotheses regarding alcohol consumption and increased risk of breast cancer. Specifically, they will study if alcohol affects estrogens in a woman's body; how alcohol increases a woman's production of harmful chemicals such as free radicals; how alcohol causes mutations in genes; and how alcohol interacts with diet to affect gene regulation and mutations.

The Center will use both experimental and epidemiology studies. Caucasian and African-American women, some with cancer and some without, will be the focal points of the epidemiology studies. The Center will consist of experts in cancer, epidemiology, basic science, biomarkers, biostatistics, radiology, medical oncology, and transgenic models.

"Today, women receive conflicting information about drinking," said Shields. "Heart specialists point out that drinking in moderation, for example a drink per day, may be protective for heart disease. But also, drinking causes cancer and other illnesses. We need to understand how drinking affects breast cancer and which women are most susceptible. Definitive studies on breast carcinogenesis may lead to improved public health recommendations, allow women to make informed individual choices about lifestyle and risk, place alcohol drinking into a broader context of interactions with other choices such diet, hormone replacement therapy, etc., and lead to more rationale prevention strategies."

The Lombardi Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 39 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington DC area. For more information, go to http://www.georgetown.edu/gumc.

Georgetown University Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.